Talphera TLPH
NASDAQ TLPH
$1.24 +0.01 (+1.23%)
As of: Sep 10, 2026 · 1:39 PM EDT

Talphera (TLPH) Non Operating Income (2010 - 2026)

Talphera (TLPH) posted Non Operating Income of -$388000.0 for Q2 2026, down 127.87% on a QoQ basis from $1.4 million in Q1 2026, and down 290.2% year-over-year from $204000.0 in Q2 2025.

Analysis

Talphera (TLPH) Non Operating Income (2010 - 2026) Analysis & Trends

Talphera has reported Non Operating Income for 17 years, with the latest figure at -$388000.0 in Q2 2026.

  • On a quarterly basis, Non Operating Income fell 290.2% year-over-year to -$388000.0 in Q2 2026; TTM through Jun 2026 was -$329000.0, a 116.65% decrease from a year earlier, with the FY2025 full-year figure at -$879000.0, down 139.1% from the prior year.
  • Non Operating Income was -$388000.0 for Q2 2026 at Talphera, down from $1.4 million in the prior quarter.
  • The five-year high for Non Operating Income was $84.3 million in Q2 2022, with the low at -$1.0 million in Q3 2025.
  • Average Non Operating Income over 5 years is $5.2 million, with a median of $250000.0 recorded in 2025.
  • The sharpest annual moves came in 2022 and 2025: Non Operating Income soared 49765.68% in 2022, then tumbled 356.06% in 2025.
  • Over 5 years, Non Operating Income stood at -$51000.0 in 2022, then tumbled by 345.1% to -$227000.0 in 2023, then soared by 596.04% to $1.1 million in 2024, then tumbled by 128.33% to -$319000.0 in 2025, then declined by 21.63% to -$388000.0 in 2026.
  • The last three Non Operating Income figures came in at -$388000.0 (Q2 2026), $1.4 million (Q1 2026), and -$319000.0 (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn -73.00 Mn
2 Gilead Sciences 180.02 Bn 176.84 Bn 6.22 Bn 387.00 Mn
3 Vertex Pharmaceuticals 131.54 Bn 123.69 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.96 Bn 73.96 Bn 3.93 Bn 234.30 Mn
5 Argenx Se 60.23 Bn 55.04 Bn 1.37 Bn -
6 Moderna 53.85 Bn 48.72 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.13 Bn 29.82 Bn 992.69 Mn -53.64 Mn
8 Biogen 31.88 Bn 30.59 Bn 1.96 Bn -
9 Roivant Sciences 29.23 Bn 29.23 Bn 1.16 Mn -
10 Talphera 93.28 Mn 93.28 Mn - -388,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -388,000.00
Mar 31, 2026 1.39 Mn
Dec 31, 2025 -319,000.00
Sep 30, 2025 -1.01 Mn
Jun 30, 2025 204,000.00
Mar 31, 2025 250,000.00
Dec 31, 2024 1.13 Mn
Sep 30, 2024 396,000.00
Jun 30, 2024 443,000.00
Mar 31, 2024 283,000.00
Dec 31, 2023 -227,000.00
Sep 30, 2023 1.89 Mn
Jun 30, 2023 -456,000.00
Dec 31, 2022 -51,000.00
Sep 30, 2022 -105,000.00
Jun 30, 2022 84.27 Mn
Mar 31, 2022 321,000.00
Dec 31, 2021 258,000.00
Sep 30, 2021 258,000.00
Jun 30, 2021 169,000.00